Sam Liao

Title: Sam Liao - Innovator in Insulin-Like Growth Factor Research

Introduction

Sam Liao is a notable inventor based in Costa Mesa, California. He has made significant contributions to the field of medical diagnostics and treatment, particularly concerning insulin-like growth factor deficiency disorders. His innovative approach has led to the development of a unique method and device that enhances the understanding and management of these disorders.

Latest Patents

Sam Liao holds a patent for a "Method and device for diagnosing and treating insulin-like growth factor deficiency disorders." This invention provides standard deviation score (SDS) calculators that are instrumental in transforming insulin-like growth factor-1 (IGF-1) concentrations into IGF-1 standard deviation scores. The patent outlines a method for calculating IGF-1 blood levels while considering IGFBP-3 blood levels, and optionally IGF-2 blood levels. This calculation aids in determining an IGF-1 production rate, which is essential for assessing the stimulated rate of IGF-1 production, especially in response to growth hormone therapy.

Career Highlights

Sam Liao is associated with Tercica, Inc., where he applies his expertise in the development of medical technologies. His work has been pivotal in advancing the understanding of growth hormone therapies and their effects on IGF-1 production.

Collaborations

Some of his coworkers include Ross Graham Clark and Gillian Clark, who serves as a Legal Representative. Their collaboration contributes to the successful implementation and protection of Liao's innovative ideas.

Conclusion

Sam Liao's contributions to the field of insulin-like growth factor research exemplify the impact of innovation in medical science. His patent and work at Tercica, Inc. highlight the importance of advancements in diagnosing and treating growth hormone-related disorders.